The signing, held in Doha on Sunday, August 17, 2025, was attended by Ambassador Igor Marara.
"This partnership strengthens healthcare cooperation between Rwanda and Qatar," the Rwandan Embassy in Qatar said in a post on X.
In a related deal, Philex Pharmaceuticals also signed a joint venture and technology transfer agreement with Rwanda's Labophar Ltd. The agreement will enable Labophar to locally manufacture Philex's solid dosage forms, boosting Rwanda's capacity to produce high-quality medicines domestically.
The deal was signed by Labophar CEO Pascal Gatete and Philex CEO Waseem Hamad.
Founded in 1983, Labophar produces a range of pharmaceutical products, including oral solutions, suspensions, and topical products. The company is currently expanding to manufacture intravenous (IV) fluids, syrups, and other products, and the partnership with Philex is expected to accelerate these efforts.
Philex Pharmaceuticals, based in Oman's Salalah Free Zone, serves markets across the Middle East, North Africa, and East Africa. The company specialises in research, development, and production of high-quality pharmaceutical and biopharmaceutical products, with a focus on generics.
The agreements mark a significant step in Rwanda's drive to improve access to affordable medicines and strengthen local pharmaceutical manufacturing.
Wycliffe Nyamasege
